Identifying and targeting the Achilles heel of a recalcitrant cancer

Targeted Therapies and Biomarkers in Small Cell Lung Cancer

(2020) Hirokazu Taniguchi et al.   Frontiers in Oncology

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

(2019) Triparna Sen et al.   Cancer Discovery

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place

(2018) Panagiotis Kotsantis et al.   Cancer Discovery

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY